AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00903162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Taken orally once a day 6-8 weeks after initial leuprolide administration
Study NCT00903162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: If desired, given intravenously every 6 months for a total of 4 injections (optional)
Study NCT03310866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic, airway
Description: classic fiberoptic bronchoscope, fenstrated airway
Study NCT03310866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic, Machintosh
Description: oral fiberoptic brochoscopic, Machintosh laryngoscope
Study NCT00507416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone for oral administration
Study NCT00507416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan for oral administration
Study NCT00507416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone for oral administration
Study NCT00507416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide for oral administration
Study NCT00883220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management of urinary catheter
Description: Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
Study NCT03209440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy - Nurse Led
Description: The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
Study NCT03209440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
Study NCT03209440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy - Chaplain Led
Description: The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
Study NCT03848611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 plus JS001
Description: CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
Study NCT04273126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Family Resilience Intervention
Description: The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
Study NCT01740388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Description: one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
Study NCT01740388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
Study NCT02769806 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Study NCT03421678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
Study NCT02436317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Of Care Ultrasound
Description: Examination with an ultrasound machine
Study NCT04144595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2 hour 75 g Oral glucose tolerance test
Description: In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded
Study NCT03814330 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sedation/Analgesia
Description: Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
Study NCT03814330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
Study NCT02629913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mementor somnium
Study NCT02629913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: wait list
Description: delayed access to mementor somnium
Study NCT02989168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: GBT440: Capsules which contain GBT440 drug substance in Swedish orange
Study NCT02914236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivaer Stylus
Description: Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
Study NCT01031966 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59 adjuvanted H1N1 influenza monovalent vaccine
Description: One/two single administration
Study NCT03242005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed® Pro-set®
Description: Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
Study NCT03242005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed® Quick-set®
Description: Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
Study NCT01995279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: French ear acupuncture
Description: Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
Study NCT01995279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Ultrasound
Description: Ultrasound turned off.
Study NCT01031966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: 1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
Study NCT01031966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: 1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
Study NCT04415736 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study
Study NCT03829137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum laser acupuncture
Description: The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
Study NCT03829137 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
Study NCT01996605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 15 mcg
Description: Oxytocin 15 mcg will be administered spinally
Study NCT00816361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
Study NCT03149458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dance
Description: dance program
Study NCT03149458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: upper limb rehabilitation
Study NCT00629265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)
Description: NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
Study NCT01996605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 150 mcg
Description: Oxytocin 150 mcg will be administered spinally
Study NCT00629265 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)
Description: NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
Study NCT01659736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Study NCT01659736 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
Study NCT00769626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
Study NCT00769626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Treatment
Description: Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
Study NCT03970837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
Study NCT03970837 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
Study NCT03970837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
Study NCT03970837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
Study NCT03970837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3196165 and Tofacitinib was administered.
Study NCT02283034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: Standard basic life support = chest compressions without any feedback device (manual resuscitation)
Study NCT02283034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CPREazy
Description: Feedback device - 3
Study NCT02283034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CPR PRO APP
Description: Feedback device - 4
Study NCT02283034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CardioPump
Description: Feedback devices - 5
Study NCT02283034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: Chest compressions without CPR feedback device (manual resuscitation)
Study NCT00735150 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire, interview
Description: You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
Study NCT04340518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral lens
Description: Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
Study NCT00077974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
Study NCT00519727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride
Study NCT01996605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo will be administered spinally
Study NCT00770536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
Description: Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
Study NCT03978832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone
Study NCT02795039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
Study NCT02795039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
Study NCT00503490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin solution for Inhalation)
Description: 40, 80, 120mg RDD
Study NCT00503490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: BID
Study NCT03569189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study.
Study NCT00583219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin
Description: A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
Study NCT00583219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (DMSO)
Description: Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
Study NCT04372303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Fatigue Resiliency Program (CFRP)
Description: The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
Study NCT02131766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiAs
Description: DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
Study NCT02131766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensor Augmented Pump Therapy
Description: Insulin pump plus CGM.
Study NCT02128087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-way SMS intervention
Description: Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours.
Study NCT02128087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-way SMS intervention group
Description: Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
Study NCT00034814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Non-enzyme-inducing TLP 35mg TID
Study NCT05925140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Kaletra is a medication that is produced by AbbVie, a pharmaceutical company based in the United States. It is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients. Kaletra contains two active ingredients, lopinavir, and ritonavir, which work together to inhibit the replication of the HIV virus.~Administration dose and duration of treatment: Patients will receive a loading dose (800/200, daily) of lopinavir 400 mg plus ritonavir 100 mg orally every 12 h for 10 days or until discharge, if sooner.
Study NCT05925140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Description: Remdesivir is provided by the United States as an FDA-approved drug, an antiviral medication developed by Gilead Sciences, and has been authorized for emergency use and approved for the treatment of COVID-19 in certain countries, including the United States.~Administration dose and duration of treatment: intravenously as a 200-mg loading dose on day 1, followed by a 100-mg once daily on days 2-10 or until hospital discharge or death. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response: For inpatients not requiring IMV and/or ECMO: 5 days; if clinical improvement is not demonstrated, treatment may be extended up to 10 days total. For inpatients requiring IMV and/or ECMO: 10 days.
Study NCT05925140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Actemra is an FDA-approved brand name for Tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, an immunosuppressive drug produced by Roche. It belongs to a class of medications known as IL-6 receptor antagonists and is designed to suppress the activity of the immune system. By blocking IL-6 receptor signaling, Actemra helps reduce inflammation and is used in the treatment of various autoimmune conditions and cytokine release syndrome.~Administration dose and duration of treatment: TCZ was administered 8 mg/kg intravenously (800 mg per infusion) as a single 60-minute intravenous infusion for 4 Weeks initially. The second infusion (400 mg) after 24 h may be administered based on clinical response in case of respiratory worsening, or 8 mg/kg at T0 followed by 8 mg/kg after 12 h.
Study NCT05925140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corticosteroid Therapy-enhanced Standard Care (CTSC)
Description: (1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins \[D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)\]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if \<80kg, or 60mg/12h if >80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally